Research
LifeSci Capital Initiates Coverage on Apnimed With Outperform Rating, $50 Price Target
$APMD
$APMD
4 stories mentioning APMDUpdated 2h ago
Every FINWIRES story that references APMD, newest first.
Research
Cantor Fitzgerald Initiates Coverage on Apnimed With Overweight Rating, $60 Price Target
$APMD
Research
Cantor Fitzgerald Initiates Apnimed at Overweight With $60 Price Target
$APMD
Research
LifeSci Capital Initiates Apnimed at Outperform With $50 Price Target
$APMD
